2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Lung Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Uterine Cervical Neoplasms
1
Support of the Family as a Caregiving System
1
Stomach Neoplasms
1
Sarcoma
1
Quality of Life
1
Pseudomyxoma Peritonei
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Pain
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Oropharyngeal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Mixed Dementias
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Maxillary Sinus Neoplasms
1
Malignant Female Reproductive System Neoplasm
1
Lymphoma, Follicular
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Referral and Consultation
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled